NPS pharma

npsNPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.

Gattex_logoThe company’s lead product, Gattex® 0.05 mg/kg/d (Teduglutide [rDNA origin]) for Injection for subcutaneous use is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects to submit its Biologic License Application (BLA) to the FDA in mid-2013. NPS’s earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates.

Advertisements

Leave a comment

March 17, 2013 · 7:18 pm

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s